Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz
Gewählte Publikation:
SHR Neuro Krebs Kardio Lipid Stoffw Microb
Veit, T; Munker, D; Barton, J; Milger, K; Kauke, T; Meiser, B; Michel, S; Zoller, M; Nitschko, H; Keppler, OT; Behr, J; Kneidinger, N.
Letermovir in lung transplant recipients with cytomegalovirus infection: A retrospective observational study.
Am J Transplant. 2021; 21(10):3449-3455
Doi: 10.1111/ajt.16718
Web of Science
PubMed
FullText
FullText_MUG
- Führende Autor*innen der Med Uni Graz
- Kneidinger Nikolaus
- Co-Autor*innen der Med Uni Graz
- Milger-Kneidinger Katrin
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- Letermovir is a new antiviral drug approved for the prophylaxis of CMV infection in allogeneic stem cell transplants. The aim of the study was to assess the therapeutic efficacy of letermovir in difficult to treat CMV infections in lung transplant recipients. All lung transplant recipients between March 2018 and August 2020, who have been treated with letermovir for ganciclovir-resistant or refractory CMV infection were included in the study and analysed retrospectively. In total, 28 patients were identified. CMV disease was present in 15 patients (53.6%). In 23 patients (82.1%), rapid response was noticed, and CMV-viral load could be significantly decreased (>1 log10 ) after a median of 17 [14-27] days and cleared subsequently in all of these patients. Five patients (17.9%) were classified as non-responder. Thereof, development of a mutation of the CMV UL56 terminase (UL-56-Gen: C325Y) conferring letermovir resistance could be observed in three patients (60%). Common side effects were mild and mostly of gastrointestinal nature. Mild adjustments of the immunosuppressive drugs were mandatory upon treatment initiation with letermovir. In addition to other interventions, letermovir was effective in difficult to treat CMV infections in lung transplant recipients. However, in patients with treatment failure mutation conferring letermovir, resistance should be taken into account.
- Find related publications in this database (using NLM MeSH Indexing)
- Acetates - administration & dosage
- Antiviral Agents - therapeutic use
- Cytomegalovirus - administration & dosage
- Cytomegalovirus Infections - drug therapy, prevention & control
- Drug Resistance, Viral - administration & dosage
- Hematopoietic Stem Cell Transplantation - administration & dosage
- Humans - administration & dosage
- Lung - administration & dosage
- Quinazolines - administration & dosage
- Retrospective Studies - administration & dosage
- Transplant Recipients - administration & dosage
- Find related publications in this database (Keywords)
- antibiotic drug resistance
- antibiotic: antiviral
- clinical research/practice, infection and infectious agents viral: Cytomegalovirus (CMV)
- infectious disease lung disease: infectious
- lung transplantation/pulmonology
- pharmacology